The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine

References

• Schmid C, Isaacson PG. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 1994;24:445–451.
   PubMed Web of Science ®Google Scholar
• Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 2014;24:71–81.
   PubMed Web of Science ®Google Scholar
• Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013;34:592–601.
   PubMed Web of Science ®Google Scholar
• Scielzo C, Apollonio B, Scarfo L, et al. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia 2011;25: 1760–1767.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96: 2655–2663.
   PubMed Web of Science ®Google Scholar
• Farahani M, Treweeke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia 2005;19: 524–530.
   PubMed Web of Science ®Google Scholar
• Natoni A, O’Dwyer M, Santocanale C. A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization. Methods Mol Biol 2013;986:217–226.
   PubMedGoogle Scholar
• Hamilton E, Pearce L, Morgan L, et al. Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. Br J Haematol 2012;158:589–599.
   PubMed Web of Science ®Google Scholar
• Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999–1006.
   PubMed Web of Science ®Google Scholar
• Ghamlouch H, Ouled-Haddou H, Damaj G, et al. A combination of cytokines rescues highly purified leukemic CLL B-cells from spontaneous apoptosis in vitro. PLoS One 2013;8:e60370.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre S, et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naive (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study. Blood 2012;120(Suppl. 1): Abstract 189.
   Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014.
   Web of Science ®Google Scholar
• Gobessi S, Laurenti L, Longo PG, et al. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007;109:2032–2039.
   PubMed Web of Science ®Google Scholar
• Chen L, Huynh L, Apgar J, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008;111:2685–2692.
   PubMed Web of Science ®Google Scholar
• Davids MS, Deng J, Wiestner A, et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012;120:3501–3509.
   PubMed Web of Science ®Google Scholar
• Calpe E, Codony C, Baptista MJ, et al. ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood 2011;118:4401–4410.
   PubMed Web of Science ®Google Scholar
• Apollonio B, Scielzo C, Bertilaccio MT, et al. Targeting B-cell anergy in chronic lymphocytic leukemia. Blood 2013;121:3879–3888.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Simeone E, Ascierto PA. The role of MEK inhibitors in the treatment of metastatic melanoma. Curr Opin Oncol 2014;26: 196–203.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Messmer D, Fecteau JF, O’Hayre M, et al. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 2011; 117:882–889.
   PubMed Web of Science ®Google Scholar
• Huber S, Oelsner M, Decker T, et al. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 2011;25:838–847.
   PubMed Web of Science ®Google Scholar
• Lopez-Guerra M, Xargay-Torrent S, Perez-Galan P, et al. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. Leukemia 2012;26:1429–1432.
   PubMed Web of Science ®Google Scholar
• Fecteau JF, Bharati IS, O’Hayre M, et al. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med 2012;18:19–28.
   PubMed Web of Science ®Google Scholar
• de Totero D, Meazza R, Capaia M, et al. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood 2008;111:517–524.
   PubMed Web of Science ®Google Scholar
• Smal C, Lisart S, Maerevoet M, et al. Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2’-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB. Biochem Pharmacol 2007;73:351–358.
   PubMed Web of Science ®Google Scholar
• Wityak J, Hobbs FW, Gardner DS, et al. Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors. Bioorg Med Chem Lett 2004;14:1483–1486.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Best OG, Gardiner AC, Majid A, et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008;22:1456–1459.
   PubMed Web of Science ®Google Scholar
• Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105–111.
   PubMed Web of Science ®Google Scholar
• Cossarizza A, Kalashnikova G, Grassilli E, et al. Mitochondrial modifications during rat thymocyte apoptosis: a study at the single cell level. Exp Cell Res 1994;214:323–330.
   PubMed Web of Science ®Google Scholar
• Tallarida RJ. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 2006;319:1–7.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.
   PubMedGoogle Scholar
• Gandhi V, Kemena A, Keating MJ, et al. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma 1993;10:49–56.
   PubMed Web of Science ®Google Scholar
• Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol 2012;920:613–626.
   PubMedGoogle Scholar
• Pettitt AR. Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br J Haematol 2003;121:692–702.
   PubMed Web of Science ®Google Scholar
• Furman RR, Cheng S, Lu P, et al. A novel mutation in Bruton tyrosine kinase confers acquired resistance to ibrutinib (PCI-32765) in CLL. Blood 2013;122(Suppl. 1):Abstract 4914.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19(2):202–208.
   PubMed Web of Science ®Google Scholar
• Niba ET, Nagaya H, Kanno T, et al. Crosstalk between PI3 kinase/PDK1/Akt/Rac1 and Ras/Raf/MEK/ERK pathways downstream PDGF receptor. Cell Physiol Bioche 2013;31:905–913.
   PubMed Web of Science ®Google Scholar
• Yu C, Mao X, Li WX. Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. Biochem Biophys Res Commun 2005;331:391–397.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009;114:4441–4450.
   PubMed Web of Science ®Google Scholar
• Barragan M, de Frias M, Iglesias-Serret D, et al. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}. J Leukoc Biol 2006;80:1473–1479.
   PubMed Web of Science ®Google Scholar
• Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, et al. Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells. Mol Med 2011;17:619–627.
   PubMed Web of Science ®Google Scholar
• Tang D, Wu D, Hirao A, et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 2002;277:12710–12717.
   PubMed Web of Science ®Google Scholar